Veliparib Plus Temozolomide for MGMT-Methylated Glioblastoma-Reply

被引：0
|
作者：
Sarkaria, Jann N. [1 ]
Kizilbash, Sani H. [1 ]
Giannini, Caterina [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
JAMA ONCOLOGY | 2025年
关键词：
D O I：
10.1001/jamaoncol.2025.0032
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma
    Weller, Michael
    Papachristodoulou, Alexandros
    Hentschel, Bettina
    Gramatzki, Dorothee
    Felsberg, Joerg
    Loeffler, Markus
    Schackert, Gabriele
    Westphal, Manfred
    Tonn, Joerg
    Silginer, Manuela
    von Deimling, Andreas
    Pietsch, Torsten
    Reifenberger, Guido
    Roth, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis
    Alnahhas, Iyad
    Alsawas, Mouaz
    Rayi, Appaji
    Palmer, Joshua D.
    Raval, Raju
    Ong, Shirley
    Giglio, Pierre
    Murad, Mohammad Hassan
    Puduvalli, Vinay
    NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)
  • [43] DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA
    Silginer, Manuela
    Papachristodolou, Alexandros
    Hentschel, Bettina
    Gramatzki, Dorothee
    Felsberg, Jorg
    Loeffler, Markus
    Schackert, Gabriele
    Westphal, Manfred
    Tonn, Jorg-Christian
    von Deimling, Andreas
    Pietsch, Torsten
    Reifenberger, Guido
    Roth, Patrick
    Weller, Michael
    NEURO-ONCOLOGY, 2018, 20 : 48 - 49
  • [44] Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide
    Thon, Niklas
    Eigenbrod, Sabina
    Grasbon-Frodl, Eva M.
    Lutz, Juergen
    Kreth, Simone
    Popperl, Gabriele
    Belka, Claus
    Kretzschmar, Hans A.
    Tonn, Joerg-Christian
    Kreth, Friedrich W.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2011, 82 (04): : 441 - 446
  • [45] QUALITY OF LIFE IN THE PHASE III CeTeG/NOA-09 TRIAL RANDOMIZING CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA
    Weller, Johannes
    Tzaridis, Theophilos
    Steinbach, Joachim
    Schlegel, Uwe
    Hau, Peter
    Krex, Dietmar
    Grauer, Oliver
    Goldbrunner, Roland
    Baehr, Oliver
    Uhl, Martin
    Seidel, Clemens
    Tabatabai, Ghazaleh
    Bullinger, Lars
    Galldiks, Norbert
    Schaub, Christina
    Stummer, Walter
    Simon, Matthias
    Fimmers, Rolf
    Matthias, Schmid
    Coch, Christoph
    Glas, Martin
    Herrlinger, Ulrich
    Schaefer, Niklas
    NEURO-ONCOLOGY, 2018, 20 : 218 - 219
  • [46] A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).
    Khasraw, Mustafa
    McDonald, Kerrie Leanne
    Rosenthal, Mark
    Lwin, Zarnie
    Ashley, David M.
    Wheeler, Helen
    Barnes, Elizabeth
    Foote, Matthew C.
    Koh, Eng-Siew
    Sulman, Erik P.
    Back, Michael
    Buckland, Michael
    Sim, Hao-Wen
    Fisher, Lauren
    Leonard, Robyn
    Hall, Merryn
    Yip, Sonia
    Simes, John
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial
    Weller, Johannes
    Tzaridis, Theophilos
    Mack, Frederic
    Steinbach, Joachim Peter
    Schlegel, Uwe
    Hau, Peter
    Krex, Dietmar
    Grauer, Oliver
    Goldbrunner, Roland
    Baehr, Oliver
    Uhl, Martin
    Seidel, Clemens
    Tabatabai, Ghazaleh
    Brehmer, Stefanie
    Bullinger, Lars
    Galldiks, Norbert
    Schaub, Christina
    Kebir, Sied
    Stummer, Walter
    Simon, Matthias
    Fimmers, Rolf
    Coch, Christoph
    Glas, Martin
    Herrlinger, Ulrich
    Schaefer, Niklas
    LANCET ONCOLOGY, 2019, 20 (10): : 1444 - 1453
  • [48] MGMT gene silencing and benefit from temozolomide in glioblastoma
    Hegi, ME
    Diserens, A
    Gorlia, T
    Hamou, M
    de Tribolet, N
    Weller, M
    Kros, JM
    Hainfellner, JA
    Mason, W
    Mariani, L
    Bromberg, JEC
    Hau, P
    Mirimanoff, RO
    Cairncross, JG
    Janzer, RC
    Stupp, R
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10): : 997 - 1003
  • [49] Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
    Thomas, Reena P.
    Recht, Lawrence
    Nagpal, Seema
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2013, 5 : 1 - 9
  • [50] Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
    Michael Castro
    Anusha Pampana
    Aftab Alam
    Rajan Parashar
    Swaminathan Rajagopalan
    Deepak Anil Lala
    Kunal Ghosh Ghosh Roy
    Sayani Basu
    Annapoorna Prakash
    Prashant Nair
    Vishwas Joseph
    Ashish Agarwal
    Poornachandra G
    Liptimayee Behura
    Shruthi Kulkarni
    Nikita Ray Choudhary
    Shweta Kapoor
    Journal of Neuro-Oncology, 2021, 153 : 393 - 402
12345